Cytokines in Acute Myocardial Infarction

Latini, Roberto; Bianchi, Marina; Correale, E; Dinarello, Charles A.; Fantuzzi, Giamila; Fresco, Claudio; Maggioni, Aldo P.; Mengozzi, Manuela; Romano, Salvatore; Shapiro, Leland; Sironi, Marina; Tognoni, Gianni; Turato, Roberto; Ghezzi, Pietro

doi:10.1097/00005344-199401000-00001

Cited by 89 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased plasma levels of IL-6 and TNF were found in patients with AMI in clinical studies by Latini et al and Suzanne et al, suggesting that TNF and IL-6 maturation, which depends on ADAM-17, may activate systemic inflammation and contribute to plaque rupture [ (Latini et al, 1994), (Engelen et al, 2022)].…”

Section: Discussionmentioning

confidence: 99%

Serum ADAM -17 and Interleukin-6 Levels as a Predictors in Type 2 Diabetic Patients with Myocardial Infarction Patients

Qalaf,

Al-Tu’ma,

Mukheef

et al. 2024

Journal-Pharmacy

View full text Add to dashboard Cite

The association of heart diseases with type 2 diabetes, especially myocardial infarction, calls for a search for biomarkers that have a relationship between the two. Which facilitates the process of reducing the development of myocardial infarction in patients with type 2 diabetes. The most prominent of these associations is long-term inflammation and its first and largest factor is interleukin 6, and its close association with A disintegrin and metalloprotease 17 (ADAM-17) and its inverse relationship with type 2 diabetic patients with and without myocardial infarction. This study aims to investigate the role of ADAM-17 in the pathogenesis of diabetic type 2 Iraqi men patients with and without MI by comparing them with a apparantely helthy as control group and to see their association with interleukin-6 levels and other biomarkers. The current study was conducted on 90 Iraqi men between Ja., 2023 and Aug. 2023, 60 samples with T2DM with or without MI and the remaining 30 as apparently healthy control. The patients were selected from the visitors of the coronary care unit (CCU) and Al-Hassan Center for Diabetes and Endocrinology in Kerbala, and they were diagnosed clinically and by laboratory investigations. Various biomarkers such as ADAM-17 and IL-6 have been determined by different biochemical techniques. As a result The highest ADAM-17 and IL-6 level in type 2 diabetes without myocardial infarction was seen as comparison serum levels of IL-6, and ADAM-17 for T2DM (with or without myocardial infarction) with the control group. The correlation between IL-6 and ADAM-17 is strong in type-2 diabetes without MI and between IL-6 and electrocardiogram represented by the two types STEM and NSTEMI in type-2 diabetes with MI. In conclusion, The current study found that ADAM-17 and IL-6 have a negative effect on chronic inflammation as in T2DM without MI is more severe than acute inflammation as T2DM with MI , du to elevation of ADAM-17 and IL-6 levels in type 2 diabetic patients without MI than type 2 diabetic patient with MI.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum ADAM -17 and Interleukin-6 Levels as a Predictors in Type 2 Diabetic Patients with Myocardial Infarction Patients

Qalaf,

Al-Tu’ma,

Mukheef

et al. 2024

Journal-Pharmacy

View full text Add to dashboard Cite

show abstract

“…Elevated levels of proinflammatory cytokines have also been associated with chronic heart failure, myocardial infarction, cardiomyopathies, cardiac transplant rejection, and atherosclerosis, although it is unclear if elevated cytokines directly contribute to cardiac pathology or if they are a biomarker of overall disease severity. 105 Elevated levels of TNF-α, IL-1, IL-6, IL-15, and IL-17 correlate to decreased functional status in patients with chronic heart failure. 106,107 The role of cytokines in chronic cardiovascular disease are reviewed elsewhere.…”

Section: Cytokines and Cardiovascular Toxicity Cardiovascular Toxicit...mentioning

confidence: 99%

Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies

Baik

Oluwole

Johnson

et al. 2021

Circulation Research

View full text Add to dashboard Cite

Immune-based therapies have revolutionized cancer treatments. Cardiovascular sequelae from these treatments, however, have emerged as critical complications, representing new challenges in cardio-oncology. Immune therapies include a broad range of novel drugs, from antibodies and other biologics, including immune checkpoint inhibitors and bispecific T-cell engagers, to cell-based therapies, such as chimeric-antigen receptor (CAR) T-cell therapies. The recognition of immunotherapy-associated cardiovascular side effects has also catapulted new research questions revolving around the interactions between the immune and cardiovascular systems, and the signaling cascades affected by T cell activation, cytokine release, and immune system dysregulation. Here, we review the specific mechanisms of immune activation from immunotherapies and the resulting cardiovascular toxicities associated with immune activation and excess cytokine production.

show abstract

Interleukin‐6 and interleukin‐1 receptor antagonist in acute stroke

Beamer

Coull

Clark

et al. 1995

Annals of Neurology

212

128

View full text Add to dashboard Cite

Elevated plasma levels of interleukin-6 (IL-6), a key regulator of the acute phase response that includes increased fibrinogen synthesis, have recently been detected in patients with acute stroke. Nevertheless, the role of the acute phase response in stroke has been controversial, with some studies suggesting that preexisting infection accounts for most of the acute phase response. Increased IL-6 could signal the involvement of antiinflammatory activity, since IL-6 stimulates the production of endogenous antiinflammatory mediators such as interleukin-1 receptor antagonist (IL-1RA). To better understand the interaction of pro- and antiinflammatory acute phase processes in brain infarction, plasma levels of IL-1RA, IL-6, and acute phase proteins including fibrinogen and c-reactive protein (CRP) were measured within 4 +/- 2 days of onset in 50 patients with acute ischemic stroke and in 20 age-matched healthy controls. After excluding patients with evidence of infection, both IL-1RA and IL-6 were significantly elevated in stoke patients compared with controls (p < 0.0001). IL-1RA and IL-6 were both significantly correlated with levels of CRP, p < 0.05 and p < 0.001, respectively, but not with each other. Levels of IL-6 and IL-1RA, together with fibrinogen and CRP were higher in patients with infarcts of greater than 3 cm and lowest in patients with lacunar syndromes.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Cytokines in Acute Myocardial Infarction

Cited by 89 publications

References 0 publications

Serum ADAM -17 and Interleukin-6 Levels as a Predictors in Type 2 Diabetic Patients with Myocardial Infarction Patients

Serum ADAM -17 and Interleukin-6 Levels as a Predictors in Type 2 Diabetic Patients with Myocardial Infarction Patients

Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies

Interleukin‐6 and interleukin‐1 receptor antagonist in acute stroke

Contact Info

Product

Resources

About